Weekly Digest - December 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - December 2024
04 Dec 2024: GSK goes East again, snagging option on preclinical DualityBio ADC for $30M
- GSK has entered into a deal with Duality Biologics to license a preclinical antibody-drug conjugate (ADC) candidate, DB-1324, for gastrointestinal cancers, with the potential deal worth up to $1 billion
- The agreement provides GSK with the option to license the ADC outside mainland China, Hong Kong, and Macau, in exchange for $30 million in upfront and pre-option milestone payments
- If GSK exercises its option, DualityBio could receive an additional fee, along with up to $975 million in development, regulatory, and commercialization milestone payments
- DualityBio’s ADC platform, used for DB-1324, employs topoisomerase-based payloads with proprietary enhancements to improve systemic stability and tumor-specific payload release, and it has attracted significant interest from other companies
